Moss Adams Wealth Advisors LLC Purchases 105 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Moss Adams Wealth Advisors LLC raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 20.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 627 shares of the medical equipment provider’s stock after acquiring an additional 105 shares during the quarter. Moss Adams Wealth Advisors LLC’s holdings in Intuitive Surgical were worth $308,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ISRG. Mirador Capital Partners LP lifted its stake in shares of Intuitive Surgical by 1.4% in the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 50 shares during the period. Advisors Asset Management Inc. increased its holdings in Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after buying an additional 1,129 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in Intuitive Surgical by 617.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after acquiring an additional 76,649 shares during the period. Brookstone Capital Management boosted its stake in shares of Intuitive Surgical by 22.4% during the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock worth $5,340,000 after acquiring an additional 2,289 shares during the last quarter. Finally, M&G Plc grew its position in shares of Intuitive Surgical by 53.5% during the 2nd quarter. M&G Plc now owns 5,069 shares of the medical equipment provider’s stock valued at $2,256,000 after acquiring an additional 1,766 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG opened at $521.15 on Friday. The business’s 50 day simple moving average is $483.85 and its 200-day simple moving average is $438.17. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $523.34. The stock has a market capitalization of $184.85 billion, a price-to-earnings ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the business earned $1.18 earnings per share. Intuitive Surgical’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ISRG shares. Wells Fargo & Company lifted their target price on Intuitive Surgical from $466.00 to $549.00 and gave the company an “overweight” rating in a research report on Friday. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a research report on Friday. Royal Bank of Canada increased their target price on shares of Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a report on Friday. JPMorgan Chase & Co. lifted their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, The Goldman Sachs Group set a $604.00 price objective on shares of Intuitive Surgical in a research note on Friday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $513.74.

Insider Activity

In related news, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.